Andre Goy, MD, MS, completed his medical degree at University Joseph Fourier in Grenoble, France, and further trained in hemato-oncology at the Faculty of Medicine Cochin Port Royal in Paris. He obtained a master’s degree in Tumor Immunology from University Pierre and Marie Curie and Pasteur Institute, Paris, and in experimental oncology from Kremlin Bicetre and Gustave Roussy Institute, Paris. Dr completed his training at the Memorial Sloan-Kettering and MD Anderson Cancer Center after joining the John Theurer Cancer Center in 2005. Dr Goy has both published in and reviewed for many journals in the fields of hematology and oncology.
Speaking on novel therapies in lymphoma
Dr Goy’s research focuses on novel therapies and improving outcomes in patients with lymphoma. He is currently involved in clinical trials of novel agents in lymphoma including Bcl-2 inhibitors and second generation kinase inhibitors. Dr Goy’s work in mantle cell lymphoma is widely recognised and he has been the lead investigator for three FDA-approved treatments, the proteasome inhibitor bortezomib, the immunomodulator lenalidomide and the BTK inhibitor ibrutinib. He has further contributed in pilot studies of the anti-CD20 monoclonal antibody, rituximab, in B-cell lymphoma.